BR0317888A - Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos - Google Patents

Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos

Info

Publication number
BR0317888A
BR0317888A BR0317888-9A BR0317888A BR0317888A BR 0317888 A BR0317888 A BR 0317888A BR 0317888 A BR0317888 A BR 0317888A BR 0317888 A BR0317888 A BR 0317888A
Authority
BR
Brazil
Prior art keywords
human growth
growth hormone
crystals
processes
preparing
Prior art date
Application number
BR0317888-9A
Other languages
English (en)
Inventor
Chandrika Govardhan
Nazer Khalaf
Benjamin Paul Simeone
Original Assignee
Altus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altus Pharmaceuticals Inc filed Critical Altus Pharmaceuticals Inc
Publication of BR0317888A publication Critical patent/BR0317888A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Abstract

"CRISTAIS DO HORMÈNIO DO CRESCIMENTO HUMANO E PROCESSOS PARA PREPARAçãO DOS MESMOS". A presente invenção refere-se a cristais estáveis, de liberação estendida, de hormónio do crescimento humano ou de um derivado de hormónio do crescimento humano e composições ou formulações compreendendo tais cristais. A invenção proporciona, adicionalmente, processos para produzir aqueles cristais e composições. A invenção proporciona adicionalmente processos para o tratamento de um indivíduo tendo distúrbios associados com deficiência de hormónio do crescimento humano ou que melhoram por tratamento com hormónio do crescimento humano, utilizando aqueles cristais e composições ou formulações.
BR0317888-9A 2002-12-31 2003-12-31 Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos BR0317888A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43751902P 2002-12-31 2002-12-31
US51704203P 2003-11-03 2003-11-03
PCT/US2003/041545 WO2004060310A2 (en) 2002-12-31 2003-12-31 Human growth hormone crystals and methods for preparing them

Publications (1)

Publication Number Publication Date
BR0317888A true BR0317888A (pt) 2005-12-06

Family

ID=32717908

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317888-9A BR0317888A (pt) 2002-12-31 2003-12-31 Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos

Country Status (12)

Country Link
US (1) US9376479B2 (pt)
EP (2) EP2460530A3 (pt)
JP (2) JP4686361B2 (pt)
KR (1) KR20050090430A (pt)
AU (2) AU2003303646B2 (pt)
BR (1) BR0317888A (pt)
CA (1) CA2512052C (pt)
DK (1) DK1581251T3 (pt)
MX (1) MXPA05007181A (pt)
RU (1) RU2357750C2 (pt)
SG (1) SG176314A1 (pt)
WO (1) WO2004060310A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4686361B2 (ja) 2002-12-31 2011-05-25 アルタス ファーマシューティカルズ インコーポレイテッド ヒト成長ホルモンの結晶およびその調製方法
WO2004060920A1 (en) * 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
EP1663296A4 (en) * 2003-09-25 2009-11-25 Cangene Corp LIQUID FORMULATION OF HUMAN GROWTH HORMONE CONTAINING POLYETHYLENE GLYCOL
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US8097584B2 (en) 2005-05-25 2012-01-17 Novo Nordisk A/S Stabilized formulations of insulin that comprise ethylenediamine
US20090060861A1 (en) * 2005-05-25 2009-03-05 Novo Nordisk A/S Stabilized Polypeptide Formulations
WO2007076131A2 (en) 2005-12-23 2007-07-05 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
MX2009001226A (es) 2006-08-04 2009-03-20 Baxter Int Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio.
ES2426485T3 (es) * 2006-08-31 2013-10-23 Novartis Ag Composiciones farmacéuticas que comprenden hGH para administración oral
JP2010513309A (ja) * 2006-12-18 2010-04-30 アルタス ファーマシューティカルズ インコーポレイテッド ヒト成長ホルモン製剤
US8367412B2 (en) 2007-02-23 2013-02-05 Kwansei Gakuin Educational Foundation Protein crystallizing agent and method of crystallizing protein therewith
WO2009009103A2 (en) * 2007-07-10 2009-01-15 Medimmune, Llc CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT
EP2111871A1 (de) * 2008-04-26 2009-10-28 Sandoz AG Stabilisierte Flüssigformulierung
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
EP2400987B1 (en) * 2009-02-25 2014-09-03 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
RU2768492C2 (ru) 2011-11-18 2022-03-24 Ридженерон Фармасьютикалз, Инк. Полимерные белковые микрочастицы
US20150158926A1 (en) * 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3064213A4 (en) * 2013-10-28 2017-04-26 Terumo Kabushiki Kaisha Protein aqueous suspension
EP3310347B1 (en) 2015-06-19 2021-08-04 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
CN113827704B (zh) * 2015-10-16 2024-07-12 瑞泽恩制药公司 稳定蛋白质组合物
KR20240006077A (ko) 2016-07-11 2024-01-12 옵코 바이오로직스 리미티드 지속성 응고 인자 vii 및 그 제조 방법
JP7104929B2 (ja) * 2017-07-24 2022-07-22 テルモ株式会社 医療用タンパク質とポリアミノ酸とを含む複合体の製造方法および医療用タンパク質とポリアミノ酸とを含む複合体
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
GB643268A (en) 1944-04-04 1950-09-15 Nordisk Insulinlab Improved process for the preparation of prolonged effect insulin products
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5618697A (en) 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
IL79681A (en) 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
DE3782737T3 (de) 1987-08-21 1999-05-20 Imcera Group Inc., Northbrook, Ill. Stabilisierung von Wachstumshormonen.
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5084350A (en) * 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
NL9000634A (nl) * 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
DE59107006D1 (de) * 1990-04-25 1996-01-18 Hoechst Ag Pharmakologische Zubereitung, enthaltend Polyelektrolytkomplexe in mikropartikulärer Form und mindestens einen Wirkstoff.
WO1991018927A1 (en) 1990-06-04 1991-12-12 Schering Corporation Method for preparing interferon alpha-2 crystals
US5780599A (en) * 1990-07-13 1998-07-14 Novo Nordisk A/S Growth hormone crystals and a process for production of growth hormone crystals
DK168790D0 (pt) * 1990-07-13 1990-07-13 Novo Nordisk As
JPH07503700A (ja) 1991-01-03 1995-04-20 アルカーメス　コントロールド　セラピューティックス，　インコーポレイテッド カチオン生体ポリマーによるタンパク質の安定化
DE4132005A1 (de) * 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
UA41502C2 (uk) 1991-12-20 2001-09-17 Ново Нордіск А/С Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5198422A (en) 1992-06-11 1993-03-30 Smithkline Beecham Corporation Stabilized somatotropin for parenteral administration
NZ255158A (en) 1992-07-31 1997-09-22 Genentech Inc Human growth hormone; stable pharmaceutically acceptable aqueous formulation and means for preparing and storing it
SE9302278D0 (sv) 1992-10-28 1993-07-02 Kabi Pharmacia Ab Growth hormone
EP1013270A3 (en) * 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
RU2143889C1 (ru) * 1993-02-23 2000-01-10 Генентек, Инк. Способ стабилизации полипептида, способы получения композиций полипептида и композиции
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5439643A (en) * 1993-11-03 1995-08-08 Liebert; Richard T. Method and apparatus for terminal sterilization
US5610134A (en) 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US5582591A (en) 1994-09-02 1996-12-10 Delab Delivery of solid drug compositions
EP0779806B2 (en) 1994-09-09 2008-04-16 Takeda Pharmaceutical Company Limited Sustained release preparation containing metal salt of a peptide
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
JPH10511964A (ja) 1995-01-13 1998-11-17 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン及びＸ−Ｌｙｓを含む安定化医薬製剤
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
ZA96122B (en) 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5788959A (en) * 1995-04-24 1998-08-04 University Of Maryland, Baltimore County Drug delivery device and method for employing the same
DE69632684T2 (de) * 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
CA2225963C (en) 1995-07-25 2008-02-05 Novartis Ag Transforming growth factor beta crystals
AU718439B2 (en) * 1995-09-21 2000-04-13 Genentech Inc. Human growth hormone variants
US5972331A (en) * 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US7276251B2 (en) 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
US5932212A (en) * 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents
ES2136458T3 (es) * 1996-06-14 1999-11-16 Takeda Chemical Industries Ltd Metodo para separar la metionina n-terminal.
ATE340259T1 (de) 1996-07-16 2006-10-15 Archibald James Mixson Kationisches vehikel: dns komplexe und ihre verwendung in gentherapie
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
ATE287257T1 (de) 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
SE9700566D0 (sv) 1997-02-18 1997-02-18 Pharmacia & Upjohn Ab Modified proteins
ES2306477T3 (es) 1997-09-05 2008-11-01 Altus Pharmaceuticals Inc. Cristales de glicoproteina reticulados por carbohidratos.
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
TR200002179T2 (tr) 1997-12-18 2001-07-23 Eli Lilly And Company Kristalin teriparatid.
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
WO1999055310A1 (en) 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
AU757991B2 (en) 1998-04-27 2003-03-13 Altus Pharmaceuticals, Inc. Stabilized protein crystals, formulations containing them and methods of making them
US6369118B1 (en) * 1998-09-09 2002-04-09 University Of Pittsburgh Biocompatible emulsifier
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1190123B1 (en) 1999-06-10 2002-10-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Encapsulation of crystals via multilayer coatings
WO2001001964A2 (en) 1999-06-23 2001-01-11 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
EP1818409A1 (en) 1999-09-09 2007-08-15 CureVac GmbH Transfer of mRNAusing polycationic compounds
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
US20040006473A1 (en) 2002-07-02 2004-01-08 Sbc Technology Resources, Inc. Method and system for automated categorization of statements
US6417237B1 (en) * 2000-06-08 2002-07-09 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes and compositions containing the same
DK1320387T3 (da) 2000-09-13 2012-07-16 Glaxosmithkline Llc Farmaceutiske sammensætninger til vedvarende afgivelse af peptider
WO2002047716A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
KR100923514B1 (ko) 2000-12-28 2009-10-27 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
CA2433361A1 (en) 2000-12-29 2002-07-11 Sidney Pestka Controlled release systems for polymers
JP2004526589A (ja) 2001-01-09 2004-09-02 イーストマン コダック カンパニー インクジェットプリントヘッドの品質管理システムおよび方法
CA2463803A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
WO2003042344A2 (en) 2001-11-13 2003-05-22 Genentech, Inc. Apo2 ligand/trail formulations
US20040029777A1 (en) * 2002-04-09 2004-02-12 Taisho Pharmaceutical Co., Ltd. Pharmaceutical preparation for taste masking
JP4686361B2 (ja) 2002-12-31 2011-05-25 アルタス ファーマシューティカルズ インコーポレイテッド ヒト成長ホルモンの結晶およびその調製方法
WO2004060920A1 (en) * 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers

Also Published As

Publication number Publication date
CA2512052A1 (en) 2004-07-22
CA2512052C (en) 2016-06-21
EP1581251B1 (en) 2016-03-16
MXPA05007181A (es) 2006-04-07
US9376479B2 (en) 2016-06-28
US20040209804A1 (en) 2004-10-21
DK1581251T3 (da) 2016-06-27
SG176314A1 (en) 2011-12-29
RU2357750C2 (ru) 2009-06-10
EP2460530A2 (en) 2012-06-06
AU2010201961A1 (en) 2010-06-03
AU2003303646A1 (en) 2004-07-29
EP2460530A3 (en) 2012-08-29
WO2004060310A8 (en) 2005-06-02
KR20050090430A (ko) 2005-09-13
EP1581251A2 (en) 2005-10-05
WO2004060310A3 (en) 2004-12-09
JP2006512416A (ja) 2006-04-13
JP4686361B2 (ja) 2011-05-25
EP1581251A4 (en) 2009-03-04
AU2003303646B2 (en) 2010-03-04
JP2010209079A (ja) 2010-09-24
WO2004060310A2 (en) 2004-07-22
RU2005124280A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
BR0317888A (pt) Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
BR0315598A (pt) Anticorpos neutralizantes contra gdf-8 e usos dos mesmos
BR0211888A (pt) Materiais e métodos para promoção de reparo de tecido nervoso
BR0317896A (pt) Complexos de cristais de proteìna e polìmeros iÈnicos
BRPI0512864A (pt) composições e métodos para o tratamento de condições e desordens oculares
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR9714415A (pt) Heterociclos contendo nitrogênio substituìdo como inibidores de proteìnas quinase p38
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
ATE268179T1 (de) Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung
ATE448686T1 (de) Actriib-fusionspolypeptide und verwendungen dafür
HUT74674A (en) Use of modafinil for preparing pharmaceutica compositions for the treatment of sleep apnoea and ventilation problems of central origin
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
ATE301654T1 (de) Naphthyridinderivate
BR9911094A (pt) Composições e métodos para o tratamento detosse
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
AU2284001A (en) Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
IL141325A0 (en) Tan-1057 derivatives
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
BR0317289A (pt) Método para tratar distúrbios do movimento usando derivados do ácido barbitúrico
BR9906975A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
MD1585G2 (ro) Remediu biostimulator
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.